The proposed Monotonous Trans cranial Magnetic Stimulation device has been used as an invasive therapy for a variety of neurological and psychiatric conditions, including schizophrenia, Parkinson's disease, and depression, throughout the last ten years. Early detection of cognitive disorders such as dementias and Alzheimer's allows patients to get higher-quality therapy that helps them retrieve the information they need and preserve their memories. The rTMS device modifies the firing pulse of neurons to initiate brain communication by providing a varying magnetic field. This problem arises because Alzheimer's disease tangles and the resulting neuronal death often begin in memory-related areas like the progress to. In clinical and research contexts, cognitive disorders are associated with difficulties; moderate cognitive disorder (MCD) in particular need a high level of diagnostic suspicion in addition to equipment that are sensitive enough to detect it. This study was out to validate the short cognitive test (CATest) for MiCD diagnosis.